Hepatitis
Hepatitis - most related articles:
-
More cases of hepatitis D reported from Sabarkantha in Gujrat - 6.5
-
Hepatitis B hits men harder than women due to an abnormal protein - 5.7
-
HIV positive have good survival rate after liver transplant - 5.4
-
New hope for hepatitis C sufferers - 4.9
-
Incivek for hepatitis C infection is approved in US - 4.7
-
Hepatitis C declines health with liver disease - 4.5
-
New biomarker predicts response to hepatitis C treatment - 4.4
-
Positive results of Albuferon in Chronic Hepatitis C - 3.9
-
Obesity enhances liver cancer risk - 2.2
-
A new drug may improve Hepatitis C - 2.2
Hepatitis articles
35 new drugs approved in 2011 in USOver the past 12 months, the U.S. Food and Drug Administration approved 35 new medicines for patients, like two new treatments for hepatitis C; a drug for late-stage prostate cancer; the first new drug for Hodgkin's lymphoma in 30 years; and the first new drug for lupus in 50 years.
Incivek for hepatitis C infection is approved in USThe U.S. Food and Drug Administration approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies.
A new drug may improve Hepatitis CIn a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.
Hepatitis B hits men harder than women due to an abnormal proteinResearchers are trying to explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women.
New biomarker predicts response to hepatitis C treatmentResearchers at Duke University Medical Center have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference.
HIV positive have good survival rate after liver transplantHIV positive and HIV negative patients have comparable survival rates following liver transplant, according to new research presented today at EASL 2009, the Annual Meeting of the European Association for the Study of Liver in Copenhagen, Denmark.
Positive results of Albuferon in Chronic Hepatitis CHuman Genome Sciences, Inc. (Nasdaq: HGSI) announced that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in combination with ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C (p=0.0008).
More cases of hepatitis D reported from Sabarkantha in GujratNearly dozen fresh cases of Hepatitis-D were reported from 3 different blocks of Sabarkantha district in Gujrat, where the liver disease has claimed 57 lives.
Hepatitis C declines health with liver diseaseAn NIH funded multi-center clinical trial found no benefit from "maintenance therapy," low-dose peginterferon used for hepatitis C patients who have not responded to an initial round of treatment.
Two HIV/TB global leaders announce merger talksFormal merger negotiations were announced between two global leaders on HIV and TB: Health & Development Networks (HDN) and the International HIV/AIDS Alliance - at the XVII International AIDS Conference which concluded in Mexico on 8_August 2008. The merger will create a new joint organisation with a global mandate, which will be part of the Alliance family.
New hope for hepatitis C sufferersUniversity of Adelaide virologists Dr Michael Beard and Dr Karla Helbig will work with colleagues from the University of NSW to develop new strategies to treat and prevent hepatitis C, which infects more than 170 million people around the world.
11 Hepatitis articles listed above.
Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.